~~<i id='D74437943F'><strike id='D74437943F'><tt id='D74437943F'><pre id='D74437943F'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

entertainment

leisure time

author：leisure time 2025-10-02 18:50:14 - browse：9

Adam's take main illustration — Molly Ferguson/STAT

Biotech is awash in PIPEs.

The numbers behind these privately negotiated purchases of public-company stock are astounding. By my count, there have been 30 PIPE transactions involving public biotechs and institutional investors (mostly hedge funds) that have raised $4 billion in the first two months of the year.

Just this week, five biotechs have brought in a combined $950 million via PIPEs, including Denali Therapeutics raising $500 million, the largest such financing this year. Crinetics Pharmaceuticals raised $350 million.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The high cost of giving birth even with insurance
Next article： Gilead might be held responsible for not developing a drug

focus

entertainment

focus

Wikipedia

entertainment

STATWhenMichaelJ.FoxwasdiagnosedwithParkinson’sdiseaseatage29,hisclearestsymptomwasasmallone—hispink

WSS

Pharmacists can make shortage drugs, but at what cost?

Doctors' information doesn't help them choose wisely when sick

PhRMA lawsuit over Medicare drug price negotiation tossed

Medicare reduced heart disease by changing how it pays doctors

CEOs share strategies for surviving biotech slump

Vaccine advisory panel ACIP left half staffed by HHS

entertainment

leisure time

focus

Novavax promises a turnaround & Lilly roils the obesity market

First Opinion Podcast: Long Covid needs a new approach

Virginia high school admissions case could be legal follow

What we’ve learned from the Aduhelm mess

DIEP, the 'gold standard' of breast reconstruction, is under threat

Senate committee scrutinizes Medicare Advantage brokers

Affirmative action in medical school literally saved lives

Lawmakers consider Medicare pay reforms for doctors

Psychedelics group wrestles with new pharma identity

A disappointing year of Humira biosimilars

entertainment

A disappointing year of Humira biosimilars

Medicare threatens to cut off funding for HCA's Mission hospital

Private equity deals in Medicare Advantage declines

First Opinion Podcast: Long Covid needs a new approach

The Readout: Gilead, Bernie Sanders, and other pharma news

Hospital price transparency does save money, advocate argues

entertainment

focus

Wikipedia

entertainment